United Therapeutics (UTHR) CEO sells 9,500 shares under 10b5-1 plan

Rhea-AI Filing Summary

UNITED THERAPEUTICS Corp Chairperson & CEO Martine A. Rothblatt exercised stock options for 9,500 shares on March 5, 2026, converting derivative securities into common stock at a reported exercise price of $146.03 per share.

On the same date, she sold a total of 9,500 common shares in a series of open-market transactions, with reported weighted-average prices ranging from $479.8871 to $487.9813, under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. Following these transactions, she directly held 130 common shares, in addition to indirect holdings reported as 166 shares by spouse and 324,518, 258,117, 45,596 and 10,962 shares held by various family trusts.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ROTHBLATT MARTINE A

(Last) (First) (Middle)

C/O UNITED THERAPEUTICS CORPORATION

1000 SPRING STREET

(Street)

SILVER SPRING MD 20910

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
UNITED THERAPEUTICS Corp [ UTHR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chairperson & CEO

3. Date of Earliest Transaction (Month/Day/Year)
03/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/05/2026		M(1)		9,500	A	$146.03	9,630	D
Common Stock	03/05/2026		S(1)		279	D	$479.8871(2)	9,351	D
Common Stock	03/05/2026		S(1)		481	D	$480.5581(3)	8,870	D
Common Stock	03/05/2026		S(1)		510	D	$482.0479(4)	8,360	D
Common Stock	03/05/2026		S(1)		1,293	D	$482.925(5)	7,067	D
Common Stock	03/05/2026		S(1)		1,728	D	$484.0481(6)	5,339	D
Common Stock	03/05/2026		S(1)		2,625	D	$484.9984(7)	2,714	D
Common Stock	03/05/2026		S(1)		798	D	$486.2033(8)	1,916	D
Common Stock	03/05/2026		S(1)		1,199	D	$487.0206(9)	717	D
Common Stock	03/05/2026		S(1)		587	D	$487.9813(10)	130	D
Common Stock								166	I	by Spouse
Common Stock								324,518	I	by Trust(11)
Common Stock								258,117	I	by Trust(12)
Common Stock								45,596	I	by Trust(13)
Common Stock								10,962	I	by Trust(14)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options	$146.03	03/05/2026		M(1)			9,500	03/15/2020	03/15/2027	Common Stock	9,500	$0.00	202,000	D

Explanation of Responses:

1. This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026.

2. This transaction was executed in multiple trades at prices ranging from $479.14 to $480.04. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

3. This transaction was executed in multiple trades at prices ranging from $480.28 to $481.24. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

4. This transaction was executed in multiple trades at prices ranging from $481.52 to $482.48. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

5. This transaction was executed in multiple trades at prices ranging from $482.52 to $483.41. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

6. This transaction was executed in multiple trades at prices ranging from $483.53 to $484.51. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

7. This transaction was executed in multiple trades at prices ranging from $484.61 to $485.58. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

8. This transaction was executed in multiple trades at prices ranging from $485.61 to $486.55. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

9. This transaction was executed in multiple trades at prices ranging from $486.62 to $487.60. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

10. This transaction was executed in multiple trades at prices ranging from $487.67 to $488.61. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

11. Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.

12. Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.

13. Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries.

14. Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.

Remarks:

	/s/ John S. Hess, Jr. under Power of Attorney	03/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did UTHR CEO Martine Rothblatt report on March 5, 2026?

Martine A. Rothblatt reported exercising options for 9,500 shares of United Therapeutics common stock and selling 9,500 shares in multiple open-market transactions on March 5, 2026. These moves converted derivative options into common stock and then monetized those shares.

At what prices did the UTHR CEO sell United Therapeutics shares?

Rothblatt’s 9,500-share sale occurred through several trades with reported weighted-average prices between $479.8871 and $487.9813 per share. Each trade price range is detailed, reflecting execution across narrow price bands in open-market transactions.

Was the United Therapeutics (UTHR) CEO sale under a 10b5-1 trading plan?

Yes. The option exercise and resulting share sale were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. The plan continues until 1,734,410 options are exercised or until December 31, 2026, whichever comes first.

How many United Therapeutics shares does the UTHR CEO hold directly after these trades?

After the reported March 5, 2026 transactions, Rothblatt directly held 130 shares of United Therapeutics common stock. This figure reflects her remaining direct ownership following the option exercise and subsequent open-market sales totaling 9,500 shares.

What indirect United Therapeutics share holdings are reported for the UTHR CEO?

Indirect holdings include 166 shares held by her spouse and 324,518, 258,117, 45,596, and 10,962 shares held by various family trusts. Footnotes state she and family members are beneficiaries and share or hold investment power over these trust positions.

What stock options did the United Therapeutics CEO exercise in this Form 4?

Rothblatt exercised 9,500 stock options on March 5, 2026, acquiring the same number of United Therapeutics common shares at an exercise price of $146.03 per share. These options were derivative securities converting into common stock as disclosed in the filing.